Zobrazeno 1 - 10
of 34
pro vyhledávání: '"N. Sapoutzis"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Klinicheskaia meditsina. 85(7)
The purpose of the study was to investigate significance of the tumor marker pyruvate kinase Tumor M2 (Tu M2-PK), in diagnostics, monitoring of treatment, and evaluation of its effectiveness in patients with lung cancer (LC). This is an isoform of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c2e05ffe409a87d43386eb88a8949975
https://pubmed.ncbi.nlm.nih.gov/17882813
https://pubmed.ncbi.nlm.nih.gov/17882813
Publikováno v:
Anticancer research. 23(2A)
Biochemical bone markers, such as the bone isoenzyme form of alkaline phosphatase, have been used to assess the bone formation phase of bone turnover in health and disease. Skeletal metastases often occur in patients with malignancies. Recent develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a5bc3fb1d9c486df15fa4e01931e89c
https://pubmed.ncbi.nlm.nih.gov/12820336
https://pubmed.ncbi.nlm.nih.gov/12820336
Publikováno v:
Anticancer research. 23(2A)
Circulating Tumor M2-PK serum levels were measured in 118 patients with various haematological malignancies. Using 17.5 U/ml as the cut-off level, elevated Tumor M2-PK concentrations were found in 7 out of 35 patients with acute myelocytic leukaemia,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1038b76182e75e1de2b231831dd56a87
https://pubmed.ncbi.nlm.nih.gov/12820361
https://pubmed.ncbi.nlm.nih.gov/12820361
Publikováno v:
Anticancer research. 23(2A)
Since tumor markers can be increased in the course of many benign diseases, the aim of this study was to verify if this also occurs in the course of rheumatic diseases.We investigated the incidence and characteristics of Tumor M2-PK in the EDTA-plasm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6ad3931692386733d641324259b99415
https://pubmed.ncbi.nlm.nih.gov/12820360
https://pubmed.ncbi.nlm.nih.gov/12820360
Autor:
G M, Oremek, N, Sapoutzis
Publikováno v:
Anticancer research. 23(2A)
Gastrin-releasing peptide (Pro-GRP), a member of the bombesin family of peptides, has been shown to have mitogenic activity in small cell lung carcinoma (SCLC), and to be produced by SCLC in an autocrine fashion. We investigated the usefulness of ser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5258c99819e7fc35cd00ea16de557e4a
https://pubmed.ncbi.nlm.nih.gov/12820319
https://pubmed.ncbi.nlm.nih.gov/12820319
Publikováno v:
Anticancer research. 23(2A)
Compared to normal tissues all tumors investigated so far and especially those with a metastatic potential overexpress an isoenzyme of the pyruvate kinase, the pyruvate kinase type tumor M2 (TU M2-PK). Because of its monomeric structure, the TU M2-PK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2705f06350694fa0ccfda1d91d20247f
https://pubmed.ncbi.nlm.nih.gov/12820364
https://pubmed.ncbi.nlm.nih.gov/12820364
Publikováno v:
Anticancer research. 23(2A)
Tumor M2-PK is an isoform of the glycolytic enzyme pyruvate kinase. This isoform exists in an active tetrameric and less active dimeric form. The dimeric form is expressed by various tumor cells and can be measured in blood by a specific ELISA.We inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed63272255ad005f7d48c9d7bd29a9a1
https://pubmed.ncbi.nlm.nih.gov/12820359
https://pubmed.ncbi.nlm.nih.gov/12820359
Publikováno v:
Anticancer research. 20(6D)
Pyruvate kinase is one of the glycolytic key enzymes. It exists in various isoforms which are expressed in different cell types. One of these isoforms, the type Tu M2-PK, is strongly overexpressed by tumor cells and released into body fluids. The con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8710088c383af09cb3f754baf58b18b3
https://pubmed.ncbi.nlm.nih.gov/11326675
https://pubmed.ncbi.nlm.nih.gov/11326675